目的探讨食管癌组织中CT10激酶调节子样蛋白(CT10 regulator of kinase like protein, CRKL)及细胞增殖核抗原Ki67的表达及与病理学特征的相关性。方法 采用免疫组化(SP)法, 检测60例食管癌组织及与其配对的56例正常癌旁组织中的CRKL及Ki67蛋白表达情况。结果 CRKL蛋白在食管癌中阳性表达率为56.7%(34/60), 明显高于在正常癌旁组织的阳性表达率5.4%(3/56, P<0.01);其表达与食管癌分化程度(P=0.027)、TMN分期(P=0.029)、浸润深度(P=0.049)及淋巴结转移 (P=0.012)有关, 与患者年龄、性别、肿瘤大小、部位无关(P>0.05)。Ki67蛋白在食管癌中阳性表达率为68.3%(41/60), 明显高于在正常癌旁组织的阳性表达率9.1%(5/56)(P<0.01);其表达与肿瘤的TMN分期(P=0.006)、淋巴结转移 (P=0.028) 有关, 与患者年龄、性别、肿瘤大小、部位、分化程度、浸润深度无关(P>0.05)。CRKL及Ki67蛋白在食管癌组织中的表达呈正相关(r=0.352, P=0.006)。结论 检测CRKL及Ki67可判断食管癌的恶性程度, CRKL可成为食管癌预后的临床预测指标及分子治疗的新靶点。

Objective To study the expressions of CRKL and Ki67 proteins in esophageal cancer and the correlation between expression and clinicopathological features. Methods Immunohistochemistry streptavidin peroxidase (SP) was designed to detect the expression of CRKL and Ki67 proteins in 60 cases of esophageal cancer tissues and 56 cases of nomally adjacent tissues. Results The positive rate of CRKL protein expression in esophageal cancer tissues and nomal controls were 56.7%(34/60)and 5.4%(3/56), respectively; there was significant difference between them(P<0.01).The expression of CRKL protein in esophageal cancer had obvious correlations with degree of differentiation (P=0.027), TMN stages (P=0.029), depth of invasion (P=0.049)and lymphatic matastasis of tumor (P=0.012);and had no correlations with age and sex of patients, size and location of tumor(P>0.05).The positive rates of Ki67 protein in esophageal cancer tissues and nomal controls were 68.3%(41/60) and 9.1%(5/56), respectively;there was significant difference between them(P<0.01). The expression of Ki67 protein in esophageal cancer had obvious correlation with TMN stages (P=0.006)and lymphatic matastasis of tumor (P=0.028); and had no correlation with age, sex, degree of differentiation, depth of invasion, size and location of tumor(P>0.05).The expression of CRKL protein had positive correlation with the expression of Ki67 protein in esophageal cancer tissue(r=0.352, P<0.01). Conclusions CRKL and Ki67 participate in the development process of esophageal cancer and it is advantageous to judge the malignant degree of tumor by detecting their expressions. CRKL can be clinical predictors of esophageal cancer and newly molecular target of clinical treatment.